ArticleCureus2025
Infliximab-Induced Vasculitis in a Rheumatoid Arthritis Patient: A Comprehensive Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF) inhibitors are widely used biologics in the management of rheumatoid arthritis (RA), but they can occasionally induce paradoxical inflammatory manifestations. We present a case of a 28-year-old female patient with well-controlled rheumatoid arthritis who developed leukocytoclastic vasculitis (LCV) secondary to infliximab therapy. Despite initial treatment with alternative biologics and corticosteroids, her condition required escalation to rituximab therapy. Histopathological examination confirmed leukocytoclastic vasculitis involving vessels in the deep dermis. After 10 months of rituximab treatment, the patient experienced complete resolution of the vasculitis. This case highlights the importance of recognizing rare but significant cutaneous adverse effects of TNF inhibitors and illustrates the challenges in management when conventional therapy proves ineffective. Clinicians should maintain vigilance for paradoxical inflammatory responses when treating patients with biologic agents and consider appropriate therapeutic alternatives when such complications arise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.